EXENATIDE (BYETTA) VS PRAMLINTIDE (SYMLIN)

艾塞那肽 (BYETTA) VS 普兰林肽 (SYMLIN)

• 批准号: 8166744
• 负责人: RUBINA A HEPTULLA
• 金额: $ 1.98万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166744
• 关键词: Adolescent; Adult; Animals; Apoptosis; Beta Cell; Child; Childhood; Computer Retrieval of Information on Scientific Projects Database; Diabetes Mellitus; Diabetic Angiopathies; Dietary Carbohydrates; Disease; Funding; Gastroparesis; Glucagon; Glucose; Grant; Hyperglycemia; Institution; Insulin; Insulin-Dependent Diabetes Mellitus; Mono-S; New Agents; Pramlintide; Protocols documentation; Reporting; Research; Research Personnel; Resources; Source; United States National Institutes of Health; analog; comparative efficacy; exenatide; glucagon-like peptide 1; glycemic control; hyperglucagonemia; improved; islet amyloid polypeptide; tool

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Type 1 diabetes mellitus (T1DM) is currently managed using modulation of dietary carbohydrates and insulin. Paradoxical post-meal hyperglucagonemia is associated with post-prandial hyperglycemia in T1DM. Glucagon suppressors such as the amylin analog, pramlintide, and the glucagon like peptide-1 (GLP-1) analog, exenatide, are new agents approved for use in adults with diabetes. We have previously demonstrated pramlintide reduces post-prandial hyperglycemia by decreasing glucagon and delaying gastric emptying in adolescents with T1DM. GLP-1 in animal studies has been shown to increase beta cell mass and decrease apoptosis. Only limited information is available on the use of GLP-1 in T1DM. No studies have been reported to determine if pramlintide and exenatide have similar effects on glycemic control in T1DM. The overall aim of this proposal is to develop safe and effective strategies targeting glucagon and improving glycemic control in pediatric T1DM. In current protocol, we hypothesize that exenatide/pramlintide will be better than insulin alone in improving glycemic control in longstanding T1DM. Secondarily comparisons between pramlintide and exenatide will be undertaken. Uses of exenatide and/or pramlintide provide us with potentially new tools to improve glycemic control in children and adolescents with T1 DM and thus reduce associated long-term microvascular complications of this debilitating disease. Postprandial glucose excursions improve with adjunctive therapy of exenatide or pramlintide with insulin as compared to mono-therapy of insulin. 1) To examine the effect of exenatide vs pramlintide adjunctive therapy in addition to insulin on glycemic control in T1DM as compared to mono-therapy of insulin. 2) To compare the efficacy of pramlintide vs exenatide when combined with insulin on glycemic control in T1DM.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 1型糖尿病（T1 DM）目前通过调节饮食碳水化合物和胰岛素进行管理。T1 DM患者餐后高胰高血糖素血症与餐后高血糖症相关。胰高血糖素抑制剂，如胰淀素类似物普兰林肽和胰高血糖素样肽-1（GLP-1）类似物艾塞那肽，是批准用于成人糖尿病的新药物。我们之前已经证明普兰林肽通过降低胰高血糖素和延迟T1 DM青少年的胃排空来降低餐后高血糖。GLP-1在动物研究中已显示增加β细胞质量并减少细胞凋亡。关于GLP-1在T1 DM中的使用，仅有有限的信息可用。尚无研究报告确定普兰林肽和艾塞那肽是否对T1 DM患者的血糖控制具有相似作用。本提案的总体目标是开发针对胰高血糖素和改善儿童T1 DM血糖控制的安全有效策略。在目前的方案中，我们假设艾塞那肽/普兰林肽在改善长期T1 DM患者的血糖控制方面优于单用胰岛素。将对普兰林肽和依塞那肽进行二次比较。艾塞那肽和/或普兰林肽的使用为我们提供了改善T1 DM儿童和青少年血糖控制的潜在新工具，从而减少这种使人衰弱的疾病的相关长期微血管并发症。 与胰岛素单药治疗相比，艾塞那肽或普兰林肽与胰岛素联合治疗可改善餐后血糖波动。 1)检查与胰岛素单药治疗相比，艾塞那肽与普兰林肽联合治疗对T1 DM血糖控制的影响。 2)比较普兰林肽与艾塞那肽联合胰岛素对T1 DM患者血糖控制的疗效。